Dasatinib

Also known as: BMS-354825, Sprycel, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide, Dasatinib anhydrous

Dasatinib (CAS 302962-49-8) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C22H26ClN7O2S and a molecular weight of 488.005 g/mol. Key properties include a melting point of 275-286°C and a density of 1.4±0.1 g/cm3. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 302962-49-8
Jingsj CID: J-47976-5
Molecular Formula: C₂₂H₂₆ClN₇O₂S
Molecular Weight: 488.005 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	275-286°C
Density	1.4±0.1 g/cm3
Exact Mass	487.155731
PSA	134.75000
LogP	2.24
Refractive Index	1.688
Storage Conditions	-20°C Freezer

Activity & Biological Data

Target	IC50: 0.6 nM/0.8 nM (AblWT/Src)[1] IC50: 79 nM/37 nM (c-KitWT/c-KitD816V)[2]
Additional Information	[1]. O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5. [2]. Shah NP, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. [3]. Chan CM, et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 1;18(13):3580-91. [4]. Shen Z, et al. Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection. J Pharm Biomed Anal. 2012 Aug-Sep;67-68:92-7. [5]. Weisberg E, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct;26(10):2233-44. [6]. Kan He, et al. Protein kinase inhibitors. Patent. US20180099960A1.

Target

IC50: 0.6 nM/0.8 nM (AblWT/Src)[1] IC50: 79 nM/37 nM (c-KitWT/c-KitD816V)[2]

Additional Information

[1]. O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5. [2]. Shah NP, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. [3]. Chan CM, et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 1;18(13):3580-91. [4]. Shen Z, et al. Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection. J Pharm Biomed Anal. 2012 Aug-Sep;67-68:92-7. [5]. Weisberg E, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct;26(10):2233-44. [6]. Kan He, et al. Protein kinase inhibitors. Patent. US20180099960A1.

Frequently Asked Questions

What is the CAS number of Dasatinib?

The CAS number of Dasatinib is 302962-49-8.

What are the molecular formula and molecular weight of Dasatinib?

Dasatinib has molecular formula C22H26ClN7O2S and molecular weight 488.005 g/mol.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Dasatinib (CAS 302962-49-8)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-47976-5 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.